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Objective: Tuberculosis (TB) has a significant impact on public health; however, its
incidence in patients with systemic necrotizing vasculitides (SNV) remains unknown.
Therefore, we evaluated the incidence of TB in patients with SNV using a nationwide
claims database.
Methods: The Health Insurance and Review Agency database was used to identify
patients diagnosed with SNV between 2010 and 2018. The standardized incidence
ratio (SIR) was calculated to compared the risk of TB between patients and the general
population, based on the 2016 annual national TB report. The incidence of TB after SNV
diagnosis was compared by estimating age- and sex- adjusted incidence rate ratio (IRR).
A time-dependent Cox regression analysis was performed to estimate factors associated
with TB.
Results: Among the included 2,660 patients, 51 (1.9%) developed TB during the
follow-up period. The risk of TB was significantly higher in patients with SNV [SIR 6.09,
95% confidence interval (CI) 4.53–8.00], both in men (SIR 5.95) and women (SIR 6.26),
than in the general population; this increased risk was consistent in all disease subtypes,
except eosinophilic granulomatosis with polyangiitis. Additionally, the incidence of TB
was the highest in patients with SNV within the first 3 months after diagnosis (adjusted
IRR: 8.90 compared to TB ≥ 12 months). In Cox regression analysis, the diagnosis of
microscopic polyangiitis [hazard ratio (HR) 3.22, 95% CI 1.04–9.99], granulomatosis with
polyangiitis (HR 4.63, 95% CI 1.53–14.02), and polyarteritis nodosa (HR 3.51, 95% CI
1.13–10.88) were independent factors associated with TB.
Conclusion: Even when considering the high incidence of TB in the
geographic region, the risk of TB increased in patients with SNV, with a
difference based on disease subtypes. Moreover, taking into account of the high
Ahn et al. TB in SNV
incidence of TB in SNV, vigilant monitoring for TB is required especially during the early
disease period.
Keywords: systemic necrotizing vasculitides, antineutrophil cytoplasmic antibody-associated vasculitis,
polyarteritis nodosa, tuberculosis, risk, incidence
INTRODUCTION
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis and transmitted via the respiratory
tract (1). It usually causes inflammation in the lungs of infected
patients but can also affect any organ in the human body,
including the lymph nodes, kidneys, central nervous system,
and bones. The formation of caseating granuloma is a typical
pathologic finding of TB, which consists of surrounding
epithelioid macrophages and lymphocytes within a central area
of necrosis (2). TB is particularly common in underdeveloped
and developing countries and has a significant impact on
global health. The World Health Organization reported that the
incidence of TB is estimated to be approximately 10.4 million
patients worldwide annually and is one of the top 10major causes
of mortality (3). Traditionally, high risk factors for developing
tuberculosis are age, male sex, smoking, malnutrition, chronic
diseases [chronic obstructive pulmonary disease (COPD),
diabetes, chronic kidney disease (CKD)], malignancies, human
immunodeficiency virus (HIV) infection, and autoimmune
inflammatory rheumatic diseases [AIRDs]) (4–8). Additionally,
treatment with immunosuppressive drugs that influence the
immune system, such as glucocorticoids and disease-modifying
anti-rheumatic drugs, is associated with the development of TB
(9–11). Accordingly, research has been continuously conducted
to investigate the incidence of TB in patients with AIRDs.
In general, the incidence of tuberculosis is significantly
increased in patients with AIRDs than in the normal population.
Rheumatoid arthritis (RA), psoriasis, and systemic lupus
erythematosus (SLE) is a prototypical AIRD involving the joint,
skin, and multiple organs. Previous studies have shown that
the incidence of TB is elevated in patients with RA, psoriasis,
and SLE (12–14). On the other hand, the occurrence of TB
can also be influenced by drugs, especially anti-TNF agents,
which are now widely used to treat RA, ankylosing spondylitis
(AS), and psoriatic arthritis (15, 16). Furthermore, a large scale
record-linkage study from the United Kingdom also suggested a
heightened TB incidence in AIRDs, including RA, AS, and SLE,
underscoring the importance of prudent monitoring for TB in
patients with AIRDs (17).
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) and polyarteritis nodosa (PAN) are
representative systemic necrotizing vasculitides (SNV) that
manifest as the development of necrotizing inflammation
within the small and medium-sized vessels (18). However,
to date, literature concerning the incidence of TB in SNV is
lacking. Although the development of national TB elimination
programmes has led to a gradual decrease in the overall
incidence and prevalence of TB, South Korea is still classified as
a TB intermediate-burden country (19). Therefore, in this study,
we investigated the incidence of TB and its related factors in
SNV using a nationwide claims database.
MATERIALS AND METHODS
Patient Selection and Data Extraction
We defined our patients as having SNV when they were
diagnosed as AAV or PAN at a general or tertiary care hospital
and were prescribed with glucocorticoids (methylprednisolone,
hydrocortisone, prednisone, prednisolone, triamcinolone,
budesonide, betamethasone, dexamethasone, or deflazacort)
during the follow-up. To select SNV cases, the corresponding
International Classification of Diseases (ICD)-10 codes
for microscopic polyangiitis (MPA), granulomatosis with
polyangiitis (GPA), eosinophilic granulomatosis with
polyangiitis (EGPA), and PAN (M31.7, M31.3, M30.1, and
M30.0, respectively) were used (20). Concerning the medications
used by patients after the diagnosis of SNV and prior to the
incidence of TB, the usage of glucocorticoids, cyclophosphamide,
rituximab, azathioprine, and methotrexate was determined.
Methotrexate dosage that was above the standard dose prescribed
for AAV (>25 mg/week) was excluded.
To acquire data of patients with SNV, we searched the
Health Insurance and Review Agency (HIRA) data from January
2008 to December 2018. HIRA database is a nationwide claims
database that contains information on the use of medical
services, including hospital visit (including hospitalization and
ambulatory care) and drug prescription for the majority of
health care users (>50 million people in South Korea) included
in the national health insurance service. In detail, HIRA
database contains information regarding age, sex, insurance type,
diagnosis, comorbidity using ICD-10 codes, prescriptions of
medications, and the utilization of healthcare related procedures
of individuals (21).
In the present study, the first date of registration of the
corresponding ICD-10 codes in the database was regarded as the
date of SNV diagnosis (index date). A 2-year washout period was
applied to exclude prevalent SNV cases. The follow-up duration
of patients was calculated from the index date of SNV until
the occurrence of TB or the last follow-up. This study was
approved by the institutional review board of the hospital and
was performed according to the principles set by the Declaration
of Helsinki. The requirement to obtain informed consent was
waived, as this study was performed retrospectively (4-2019-
0177).
Definition of TB in Patients With SNV and
Investigation of Comorbidities
Patients with SNV who were assigned the ICD-10 codes of TB
(A15-19) after SNV diagnosis and were prescribed with at least
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FIGURE 1 | Flowchart for patient selection and data extraction. SNV, systemic necrotizing vasculitides, MPA, microscopic polyangiitis; GPA, granulomatosis with
polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa; TB, tuberculosis; ICD, international classification of diseases.
two of the first-line drugs for TB (isoniazid, rifampin/rifampicin,
pyrazinamide, ethambutol) at the date of TB diagnosis were
defined as incident TB cases (22–24). The number of expected
cases with TB was calculated by multiplying the person-years of
patients with AAV and age- and sex-specific TB incidence rate
based on the 2016 annual national TB report (25).
The investigated comorbidities associated with TB included
the presence of hypertension (ICD-10 code I10-15), diabetes
mellitus (E10-14), CKD (N18), COPD (J43-44), HIV infection
(B20-24), and silicosis (J62), which were searched for using the
ICD-10 codes of patients within 1 year of the index date of SNV.
Statistical Analysis
Continuous and categorical variables were presented as mean ±
standard deviation and frequencies (percentages). The Student’s
t-test was used to compare continuous variables, and the chi-
square or Fisher’s exact tests were used to compare categorical
variables, as appropriate. Patients were divided into 10-year
intervals by age, and standardized incidence ratios (SIRs) of the
corresponding interval were calculated to compare the incidence
of TB between patients with SNV and in the general population.
SIRs were estimated by dividing the number of observed cases by
that of expected cases, and the 95% confidence interval (CI) was
estimated using Poisson distribution. To compare the incidence
of TB after SNV diagnosis, the incidence rate per 1,000 person-
years and an age- and sex- adjusted incidence rate ratio (IRR)
were estimated by dividing the intervals into four groups (TB <3
months, 3 ≤ TB < 6 months, 6 ≤ TB < 12 months, and TB ≥
12 months). The Kaplan-Meier method and log-rank test were
used to the estimate and compare cumulative incidence rates of
TB according to disease subtypes.
To investigate clinical factors associated with TB in patients
with SNV, a time-dependent Cox regression analysis was
performed. Age, sex, type of diagnosis, insurance status,
and comorbidities were included as time-fixed variables. In
addition, in order to avoid length bias, the administration of
immunosuppressive agents of glucocorticoid usage ≥12 months,
cyclophosphamide, azathioprine, methotrexate, and rituximab
was included as time-dependent variables to calculate the hazard
ratios (HRs) of TB occurrence. In all statistical analyses, P-value
< 0.05 was considered significant, and SAS 9.4 Enterprise Guide
(SAS Institute, Inc.) and R 3.6.1 (R Foundation for Statistical
Computing, Vienna, Austria) were used for all statistical analyses.
RESULTS
Clinical Characteristics of SNV Patients
With TB and Without TB
At baseline, 2,984 incident cases of SNV were searched. Among
them, 324 patients were excluded because of a previous history of
TB (Figure 1). The mean age of the remaining 2,660 patients was
57.5 years, and 54.8% were women. MPA was the most common
diagnosis (34.8%) within SNV, followed by EGPA, GPA, and PAN.
During the mean follow-up period of 3.3 years and 8,796.85
person-years, 51 patients (1.9%) developed TB and 2,609 (98.1%)
did not. The mean follow-up duration was 1.4 years (median 0.5
years and 72.14 person-years) for patients with TB and 3.3 years
(median 2.8 years and 8,724.71 person-years) for those without
TB (P < 0.001). Comparison of baseline characteristics between
the two groups showed no significant difference in age, sex,
insurance status, and the presence of comorbidities. However,
the proportion of patients with EGPA was lower in patients with
TB [7.8% in the TB (+) group and 22.6% in the TB (–) group],
and the proportion of patients prescribed glucocorticoids for≥12
months and azathioprine was significantly lower in the TB group
(P < 0.001 and P = 0.013) (Table 1).
Calculation of TB Risk in Patients With SNV
To assess the risk of TB in patients with SNV, the incidence of
TB was calculated, and SIRs were obtained by comparing to the
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TABLE 1 | Clinical characteristics of patients with SNV at initial diagnosis.
Total patients n = 2,660 Patient with TB n = 51 Patient without TB n = 2,609 P-value
Age, years 57.5 ± 16.9 59.1 ± 18.1 57.5 ± 16.8 0.502
Sex, n (%) 0.208
Male 1,203 (45.2) 28 (54.9) 1,175 (45.0)
Female 1,457 (54.8) 23 (45.1) 1,434 (55.0)
Diagnosis [ICD-10 code], n (%) 0.037
MPA 925 (34.8) 17 (33.3) 908 (34.8)
GPA 583 (21.9) 17 (33.3) 566 (21.7)
EGPA 593 (22.3) 4 (7.8) 589 (22.6)
PAN 559 (21.0) 13 (25.5) 546 (20.9)
Follow-up duration, years 3.3 ± 2.7 1.4 ± 2.0 3.3 ± 2.7 <0.001
Type of TB, n (%)
Pulmonary TB [A15, 16, 19] 43 (84.3) 43 (84.3)
Extrapulmonary TB [A17-18] 8 (15.7) 8 (15.7)
Insurance status, n (%) 1.000
National Health Insurance 2,550 (95.9) 49 (96.1) 2,501 (95.9)
Medical Aid 110 (4.1) 2 (3.9) 108 (4.1)
COMORBIDITIES [ICD-10 CODE], n (%)
Hypertension [I10-15] 1,255 (47.2) 27 (52.9) 1,228 (47.1) 0.490
Diabetes mellitus [E10-14] 899 (33.8) 19 (37.3) 880 (33.7) 0.706
Chronic kidney disease [N18] 349 (13.1) 11 (21.6) 338 (13.0) 0.111
Chronic obstructive pulmonary disease [J43-44] 427 (16.1) 9 (17.7) 418 (16.0) 0.904
HIV infection [B20-24] 0 (0.0) 0 (0.0) 0 (0.0) n/a
Silicosis [J62] 0 (0.0) 0 (0.0) 0 (0.0) n/a
IMMUNOSUPPRESSIVE AGENTS USAGE, n (%)
Glucocorticoid usage ≥ 12 month 1,246 (46.8) 10 (19.6) 1,236 (47.4) <0.001
Cyclophosphamide 1,153 (43.4) 18 (35.3) 1,135 (43.5) 0.304
Azathioprine 992 (37.3) 10 (19.6) 982 (37.6) 0.013
Methotrexate 433 (16.3) 7 (13.7) 426 (16.3) 0.759
Rituximab 258 (9.7) 3 (5.9) 255 (9.8) 0.476
Values are expressed as mean (standard deviation) or in number (percentages).
SNV, systemic necrotizing vasculitides; TB, tuberculosis; ICD, international classification of diseases; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA,
eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa; HIV, human immunodeficiency virus.
general population based on the 2016 annual national TB report.
Overall, the risk of TB in SNV was higher in patients with SNV
than in the general population (SIR 6.09, 95% CI 4.53–8.00) and
was consistently higher for all subtypes of SNV, except EGPA
(SIR 2.14, 95% CI 0.58–5.48) (Figures 2, 3). On comparing the
risk of TB according to 10-year age intervals, the risk of TB was
significantly higher in all age groups of SNV, except for those aged
0–19 and 50–59 years. In particular, SIRs of TB were the highest
in patients aged 20–29 and 30–39 years (SIR 14.30, 95% CI 3.90–
36.62; SIR 14.86, 95% CI 4.83–34.68). The risk of TB was equally
high in patients with SNV regardless of sex (SIR 5.95, 95% CI
3.96–8.60 inmen and SIR 6.26, 95%CI 3.97–9.39 in women). The
risk of TB was not elevated in either men or women with EGPA
(Figures 2, 3).
On calculating the risk of TB according to medication usage,
the risk of TB was significantly higher in patients with SNV
treated with immunosuppressive agents than in the general
population (Figure 4). When we divided patients as per the
disease subtypes and compared the cumulative incidence rate of
TB, a significant difference was found in the occurrence of TB;
the cumulative incidence of TB was the lowest in patients with
EGPA (log-rank test P = 0.034) (Figure 5).
Risk of TB in Patients With SNV After
Disease Diagnosis
Next, we evaluated whether the risk of TB differed in patients
with SNV according to the period after diagnosis. When the
incidence of TB was calculated in the patients after disease
diagnosis, the incidence rate/1,000 person-years was especially
higher in TB < 3 months (26.07/1,000), followed by 3 months
≤ TB < 6 months (18.06/1,000), 6 months ≤ TB < 12 months
(6.94/1,000), and TB ≥ 12 months (2.72/1,000). Furthermore,
IRR of TB in SNV within 3 months of diagnosis was significantly
higher than TB ≥ 12 months in the unadjusted (IRR 9.59
compared to TB ≥ 12 months, 95% CI 4.89–18.81) and in age-
and sex-adjusted (IRR 8.90 compared to TB≥ 12months, 95%CI
4.52–17.53) analyses (Table 2). In all disease types, the incidence
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FIGURE 2 | Assessment of the risk of TB in patients with SNV according to age and sex. The overall SIR of TB was estimated in patients with SNV compared to the
general population. TB, tuberculosis; SNV, systemic necrotizing vasculitides; SIR, standardized incidence ratio; CI, confidence interval.
rate of TB was higher during the early period after diagnosis
(Table 3).
Factors Associated With the Risk of TB in
Patients With SNV
In the unadjusted Cox regression analysis, the diagnoses of MPA
(HR 3.45, 95% CI 1.16–10.26), GPA (HR 4.58, 95% CI 1.54–
13.62), PAN (HR 3.20, 95% CI 1.04–9.81), and the comorbidity
of CKD (HR 2.20, 95% CI 1.13–4.29) were significant factors
associated with TB. However, in the adjusted analysis, only the
diagnoses of MPA (HR 3.22, 95% CI 1.04–9.99), GPA (HR 4.63,
95% CI 1.53–14.02), and PAN (HR 3.51, 95% CI 1.13–10.88) were
significantly associated with the increased risk of TB (Table 4).
DISCUSSION
Accumulating evidence now indicate that the risk of TB is
elevated in patients with AIRDs; however, the incidence of TB in
patients with SNV remains unclear. In this study, we evaluated
the incidence of TB in patients with SNV using the National
Health Insurance Claims Database. Our results revealed that
1.9% (n = 51) of the patients developed TB during follow-
up. Remarkably, the risk of TB was over six times higher in
patients with SNV than in the general population, consistent with
findings of previous studies that demonstrated increased risks of
TB in patients with AIRDs. Moreover, the risk of TB was the
most pronounced within the first 3 months after SNV diagnosis.
Among disease subtypes, the risk of TB was elevated in patients
with MPA, GPA, and PAN, and the highest risk was observed
in GPA compared to the general population. The strength of
this study is that, to the best of our knowledge, this is the first
to evaluate the incidence of TB in patients with SNV using a
nationwide database.
Two possible hypotheses could be drawn regarding the
increased risk of TB in SNV found in this study. First, in
the pathogenesis, of SNV, abnormalities of the innate and
adaptive immune systems are responsible for the development
of chronic inflammation and perpetuation of the vicious cycle
(26). Accumulating evidences now suggest that a defect in
adaptive immune response, especially T cells, is important in the
pathogenesis of SNV (27). Similarly, hampered clearance of TB
by the immune system is important in the development of TB,
and the generation of effective CD4+ T-cell response is crucial in
the host defense against TB (28). Therefore, the incidence of TB
may be higher in patients with SNVdue to functional impairment
of host immunity. Second, continuous administration of
glucocorticoids and immunosuppressive drugs could also be
attributable to the development of TB. Glucocorticoids and
immunosuppressive drugs have been demonstrated to exhibit
broad effects on suppressing the immune response, as well
as inhibiting T-cell activation and differentiation (29–32).
Accordingly, the use of glucocorticoids and immunosuppressive
drug may be associated with the risk of TB.
Although the incidence of TB in South Korea is decreasing,
TB remains to be one of the most important public health issues
in this endemic region, owing to the high infectivity and difficulty
to effectively treat at-risk populations (33). According to the 2016
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FIGURE 3 | Assessment of the risk of TB in SNV subtypes according to age and sex. The SIR of TB was estimated in patients with MPA, GPA, EGPA, and PAN
compared to the general population. TB, tuberculosis; SNV, systemic necrotizing vasculitides; SIR, standardized incidence ratio; MPA, microscopic polyangiitis; GPA,
granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa; CI, confidence interval.
FIGURE 4 | The risk of TB in patients with SNV according to immunosuppressive agent usage. The risk of TB was calculated in patients with SNV compared to the
general population according to immunosuppressive agent usage. TB, tuberculosis; SNV, systemic necrotizing vasculitides; SIR, standardized incidence ratio; CI,
confidence interval.
World Health Organization TB estimates, the incidence of TB is
77 cases per 100,000 persons in South Korea, which was higher
than in the United States or European countries (2.9 cases per
100,000 persons in United States; 31.6 cases per 100,000 persons
in Europe) (3, 34). However, even when considering the high
incidence of TB in the geographic region, our findings have
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FIGURE 5 | Comparison of cumulative TB incidence rate among SNV subtypes. TB, tuberculosis; SNV, systemic necrotizing vasculitides; GPA, granulomatosis with
polyangiitis; PAN, polyarteritis nodosa. MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis.
TABLE 2 | Incidence rate ratio of TB in patients with SNV according to the interval after diagnosis.
Total
After diagnosis # of Events PY IR/1,000 PY (95% CI) Crude IRR (95% CI) Adjusted IRR (95% CI)¶
TB < 3 months 16 613.83 26.07 (15.29–41.00) 9.59 (4.89–18.81) 8.90 (4.52–17.53)
3 months ≤ TB < 6months 10 553.74 18.06 (9.05–31.67) 6.63 (3.06–14.37) 6.27 (2.89–13.61)
6 months ≤ TB < 12 months 7 1,008.50 6.94 (2.98–13.42) 2.55 (1.07–6.11) 2.44 (1.02–5.84)
TB ≥12 months 18 6,620.78 2.72 (1.65–4.17) 1.00 (Ref) 1.00 (Ref)
¶ IRR was calculated by adjusting for age and sex.
TB, tuberculosis; SNV, systemic necrotizing vasculitides; PY, person-years; IR/1,000 PY, incidence rate/1,000 person-years; CI, confidence interval; IRR, incidence rate ratio.
revealed that SIR for TB was over six times (SIR 6.09) in patients
with SNV than in the general population, and the increased risk
of TB was identical regardless of sex. Moreover, the risk of TB was
consistently elevated in all age groups, only except in those aged
<20 and 50–59 years. Although the incidence of tuberculosis
increases with age in the general population according to the
2016 annual national TB report, SIRs of TB were higher in
younger patients with SNV (25). These findings imply that careful
monitoring is necessary for these patients at all age groups for
the development of TB. However, given that older patients are
more likely to drop-out as a result of highermortality, it is unclear
whether this observation is related to higher TB susceptibility in
younger SNV patients or is a consequence of higher mortality
rates and drop-out of older SNV patients, which should be
verified through future investigations.
The incidence of TB was particularly higher within the first 3
months of SNV diagnosis. Because the normal immune response
is compromised in patients with SNV, patients may be more
subject to TB during the early phase of SNV diagnosis, in
which perturbation of the immunity is the most prominent.
Furthermore, immunosuppressants aremost actively used during
the early stages to achieve disease remission; thus, the incidence
of TB could increase during the early phase of the disease
because of the higher requirement of immunosuppressive
drugs. However, although patients with SNV treated with
immunosuppressive agents exhibited an equally increased risk
of TB compared to the general population, the association
between immunosuppressive agents and the occurrence of
TB in SNV was not found in the Cox regression analysis,
suggesting that drugs used to treat SNV did not have a
significant impact in the development of TB by themselves.
This discrepancy could be attributed to the largely variable
incidence of TB in chronic inflammatory diseases (35). The
difference in the geographies, ethnicity, and diseases investigated
might have also influenced our results. Moreover, the risk of
TB in those undergoing immunosuppressive treatment may be
increased in a dose-dependent manner, and the dose of drugs
used were not sufficiently high to provoke TB (36). However,
because we could not evaluate detailed drug dosages for the
patients, further studies are required to better understand the
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relationship between immunosuppressants and the risk of TB
in SNV.
In the subgroup analysis according to disease subtypes of
SNV, the risk of TB was significantly higher in all subtypes
than in the general population, except for EGPA. Among the
disease subtypes, the risk of TB was the highest in patients
with GPA. Furthermore, in Cox regression analysis, the HR
of GPA was the highest within SNV subtypes. Although the
exact cause of this disease specific-predisposition is unclear,
it could be related to GPA being defined as necrotizing
granulomatous inflammation most commonly involving the
upper and lower respiratory tracts (37). Radiographic findings
of nodular, cavitary lesions, and consolidations in the lung
parenchyma are common in patients with GPA (38). Considering
that chronic inflammation in the respiratory tracts is associated
with TB (39), it could be hypothesized that the risk of TB is
elevated in patients with SNV, especially GPA. Nevertheless, as
asthma and pulmonary involvement are also often present in
EGPA, additional investigations are necessary to elucidate why
patients with EGPA are less susceptible to TB. Meanwhile, as
imaging findings of GPA can be difficult to discriminate from
those of TB, a pathological confirmation to exclude the possibility
of TB is essential if a clinical diagnosis of TB is suspected.
In the present study, the number of patients with
extrapulmonary TB was 8 (15.7%), which seems to be
numerically similar to the proportion of extrapulmonary
TB arising in immunocompetent subjects and is contradictory
to the knowledge that patients under TNF-α inhibitors are more
prone to extrapulmonary TB (40). In addition, even though the
number of incident TB cases were not large, a recent publication
by Chung et al. reported that a proportion of extrapulmonary
TB in patients with rheumatoid arthritis (RA) was 38.5% (41),
and a study by Vuorela et al. has shown that ∼23.9% of patients
with rheumatic diseases are affected with extrapulmonary TB
(42). Several factors could be accounted for the discrepant
results between the previous studies and our study. Even though
TNF-α inhibitors increases the risk of extrapulmonary TB,
TNF-α blocking agents are not generally recommended for
the treatment of SNV (43). Therefore, the high incidence of
extrapulmonary TB in a RA cohort could be explained by
the frequent use of TNF-α inhibition for RA treatment. In
addition, it is also possible that a difference between AIRDs
could be present concerning the development of pulmonary
or extrapulmonary TB, especially in SNV. Finally, because our
study was conducted only by using the ICD-10 codes of the
patients, the clinical details may not be sufficiently reflected in
classifying as pulmonary and extrapulmonary TB.
Several limitations are present in this study. First, clinical
details regarding SNV, including disease severity, patterns of
organ involvement, and laboratory data, were not available.
Second, because there are no established criteria to identify SNV
and TB using administrative data, differences in the definition
used to define SNV and TB might have influenced patient
selection. In particular, identification of TB cases by using the
ICD-10 codes and 1st line medications should be further verified
in population based studies. Third, the clinical outcome of
patients affected with TB and the effect of TB medications may
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TABLE 4 | Factors associated with the occurrence of TB during follow-up.
Crude hazard ratio Adjusted hazard ratio
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age‡ 1.02 (0.99–1.03) 0.087 1.01 (0.99–1.03) 0.412
SEX‡
Male 1.55 (0.89–2.69) 0.119 1.48 (0.85–2.60) 0.168
Female 1.00 (Ref) 1.00 (Ref)
DIAGNOSIS‡
MPA 3.45 (1.16–10.26) 0.026 3.22 (1.04–9.99) 0.043
GPA 4.58 (1.54–13.62) 0.006 4.63 (1.53–14.02) 0.007
EGPA 1.00 (Ref) 1.00 (Ref)
PAN 3.20 (1.04–9.81) 0.042 3.51 (1.13–10.88) 0.030
INSURANCE STATUS‡
National health insurance 1.00 (Ref) 1.00 (Ref)
Medical aid 0.95 (0.23–3.91) 0.946 1.06 (0.29–3.87) 0.926
COMORBIDITIES‡
Hypertension 1.49 (0.86–2.59) 0.156 1.11 (0.58–2.11) 0.751
Diabetes mellitus 1.31 (0.74–2.32) 0.346 1.06 (0.57–1.96) 0.852
Chronic kidney disease 2.20 (1.13–4.29) 0.021 1.77 (0.83–3.75) 0.138
Chronic obstructive pulmonaryDisease 1.23 (0.60–2.53) 0.568 1.45 (0.68–3.08) 0.336
IMMUNOSUPPRESSIVE AGENTS USAGE†
Glucocorticoid usage ≥ 12 month 0.86 (0.30–2.50) 0.787 1.10 (0.36–3.30) 0.870
Cyclophosphamide 0.87 (0.49–1.54) 0.628 0.76 (0.41–1.40) 0.381
Azathioprine 0.64 (0.32–1.31) 0.222 0.62 (0.30–1.28) 0.199
Methotrexate 1.11 (0.50–2.44) 0.799 1.01 (0.44–2.33) 0.974
Rituximab 1.12 (0.37–3.35) 0.840 0.91 (0.29–2.82) 0.871
‡Age, sex, type of diagnosis, insurance status, and comorbidities were included as time-fixed variables.
†
Glucocorticoid usage ≥12 months, cyclophosphamide, azathioprine, methotrexate, and rituximab usage were included as time-dependent variables.
TB, tuberculosis; CI, confidence interval; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN,
polyarteritis nodosa.
not be fully addressed through the HIRA data. Fourth, it remains
unclear whether patients were routinely screened and treated for
latent TB before immunosuppressive treatment and pre-emptive
therapy for high-risk individuals (e.g., those with latent TB or
elderly patients) are required to reduce the risk of TB.
In conclusion, patients with SNV were prone to TB than the
general population. The risk of TB was higher within the first
3 months after SNV diagnosis, and it was highest in those with
GPA among the disease subtypes. Our findings emphasize that
vigilant monitoring for the occurrence of TB is required in the
management of patients with SNV, especially during the early
disease period.
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